Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gunma
Clinical trial register · Japan

Clinical Trials in Gunma, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline13 Janssen Research & Development, LLC8 NRG Oncology4 Ono Pharmaceutical Co., Ltd.3 Novo Nordisk A/S3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Gunma

40 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
Hoffmann-La Roche
Phase 3
380
Toyohashi, Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama
2026-06-23
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo
2026-05-31
Recruiting
GlaxoSmithKline
Phase 2
200
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai
2026-04-15
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Gunma, Okayama
2026-02-08
Recruiting
GlaxoSmithKline
Phase 3
1,250
Gunma, Kagoshima
2025-12-12
Recruiting
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823Agitation Associated With Alzheimer's Disease Dementia
DrugONO-2020
Ono Pharmaceutical Co., Ltd.
Phase 2
90
Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido
2025-05-01
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Aichi, Chiba, Fukushima, Gunma, Hiroshima, Hyōgo, Ibaraki, Kagawa
2025-04-24
Active, closed
Philip Morris Products S.A.
Not applicable
290
Fukuoka, Gunma, Hyōgo, Tokyo, Yamagata, Yokohama, Yotsuya
2025-04-02
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
DrugsIBI305·HD204·Bevacizumab-awwb·BP102
NRG Oncology
Phase 3
880
Sendai, Tōon, Kure, Sapporo, Akashi, Shiwa-gun, Kagoshima, Gunma
2025-03-12
Recruiting
GlaxoSmithKline
Phase 3
520
Shibuya-Ku, Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki
2024-12-16
Recruiting
GlaxoSmithKline
Phase 3
514
Aichi, Gunma, Hiroshima, Hokkaido, Tokushima, Tokyo, Yamanashi
2024-12-12
Recruiting
GlaxoSmithKline
Phase 2
393
Chiba, Ehime, Gunma, Hokkaido, Kagawa, Nara, Niigata, Osaka
2024-09-27
Active, closed
Software as a Medical Device for the Treatment of Patients With PTSD
NCT06589505Post-Traumatic Stress Disorder, PTSD
Otsuka Medical Devices Co., Ltd. Japan
Phase 2/3
52
Yamanashi, Akita, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2024-09-01
Active, closed
GlaxoSmithKline
Phase 2
41
Aichi, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo, Ibaraki
2024-05-07
Recruiting
GlaxoSmithKline
Phase 3
864
Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo
2024-03-21
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Fukuoka, Fukutsu, Gifu, Ginowan, Gunma, Hokkaido, Isehara, Itabashi Ku
2024-01-17
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 1/2
85
Gunma, Tokyo, Yamaguchi
2024-01-04
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Gunma, Hiroshima, Hokkaido, Kanagawa, Miyagi, Shizuoka, Tokushima, Tokyo
2023-09-13
Active, closed
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
AstraZeneca
Observational
416
Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma
2023-04-04
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Bunkyō City, Chiba, Gifu, Gunma, Hirakata, Hitachi, Iruma-gun, Kamogawa
2023-03-29
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Aichi, Gunma, Nara, Saitama, Tochigi, Tokyo
2023-02-13
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Sapporo, Suita-shi, Aichi, Chiba-shi, Chiba, Gunma, Kanagawa, Osaka, Saitama
2022-11-01
Active, closed
NRG Oncology
Phase 3
237
Sapporo, Gunma, Kyoto, Showa-Ku Nagoya, Tokyo
2022-10-24
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Bunkyō City, Chiba, Fukuoka, Gifu, Gunma, Hirakata, Hyōgo, Kamakura-shi
2022-10-13
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
Active, closed
Novo Nordisk A/S
Observational
200
Amagasaki-shi, Hyogo, Chuo-shi, Yamanashi-ken, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka, Gifu, Goshogawara-shi, Aomori-ken, Gunma
2022-02-03
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bunkyō City, Chūōku, Fukui-ken, Fukuoka, Fukuyama, Gamagōri, Gunma, Hachinohe
2022-01-19
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Bunkyō City, Gunma, Ikoma, Kurume, Saitama Shi, Sendai, Setagaya Ku, Tsu
2021-10-18
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
GlaxoSmithKline
Phase 3
302
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Numakunai, Okayama
2020-10-01
Active, closed
GlaxoSmithKline
Phase 3
242
Chiba, Ehime, Fukui, Gunma, Hiroshima, Hokkaido, Kagawa, Kanagawa
2020-07-14
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Active, closed
GlaxoSmithKline
Phase 3
325
Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido
2020-04-02
Active, closed
Amicus Therapeutics
Phase 3
21
Osaka, Gunma, Miyagi, Tokyo
2020-02-13
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/gunma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Gunma.

How many clinical trials are recruiting in Gunma?

14 of the 40 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gunma), 40 studies
PhaseStudiesRecruitingShare
Phase 326965%
Phase 26315%
Not applicable205%
Observational205%
Phase 2/3215%
Phase 1/2102.5%
Phase 4112.5%

Most active sponsors

Lead sponsors with the most studies (Gunma)
Lead sponsorStudiesRecruiting
GlaxoSmithKline138
Janssen Research & Development, LLC81
NRG Oncology43
Novo Nordisk A/S30
Ono Pharmaceutical Co., Ltd.31
Amicus Therapeutics10
AstraZeneca10
Hoffmann-La Roche11
Ionis Pharmaceuticals, Inc.10
National Cancer Institute (NCI)10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.